CMFP protocol

1.	Neoplasms (Cancer) 03/01/1996 - "Patients with larger tumors in the CMFp regimen were especially subject to this increase with a RR for failure in the skeleton of 3.32 (95% CI, 1.57 to 7.02; P = 0.0005). " 07/01/1989 - "Relapse-free status was actually worse for CMFP-treated patients with ER-positive tumors, but not significantly so (P = .15). " 01/01/1986 - "Treatment with CMFp + T reduced local, regional, and distant metastases and was equally effective in improving DFS in patients with ER-positive or ER-negative tumors. " 10/01/1997 - "Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides control of metastatic cancer comparable to that of CMFP combination therapy when used as front-line therapy in an outpatient setting." 04/01/1997 - "Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides comparable control of metastatic cancer to CMFP combination therapy when used as front-line treatment." Order ALL the reference details at left...
2.	Neoplasm Metastasis (Metastasis) 01/01/1990 - "Analysis of sites of first relapse showed that the difference between the two treatment groups can be entirely attributed to the reduction in bone metastases in the oophorectomized group (Ox + CMFp). " 01/01/1986 - "Treatment with CMFp + T reduced local, regional, and distant metastases and was equally effective in improving DFS in patients with ER-positive or ER-negative tumors. " 01/01/1986 - "In this randomized trial of 463 postmenopausal women 65 years of age or younger with axillary node metastases, treatment with the combination of CMF plus low-dose prednisone and tamoxifen (CMFp + T), was compared to endocrine therapy alone (p + T) or to no further treatment after total mastectomy and axillary clearance. " 12/01/1986 - "Between 1978 and 1981, 463 evaluable postmenopausal patients 65 years of age or younger with operable breast cancer and metastases in axillary lymph nodes were entered in Ludwig Breast Cancer Study III (Ludwig III) and randomly allocated to receive chemoendocrine therapy with cyclophosphamide, methotrexate, 5-fluorouracil, low-dose continuous prednisone, and tamoxifen (CMFp + T) for 12 monthly cycles, or endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year, or no adjuvant treatment after mastectomy (observation). " 06/09/1984 - "Adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastasis was assessed; chemo-endocrine therapy (cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen; CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen; p + T), and with no adjuvant treatment in 463 patients aged less than or equal to 65 years. " Order ALL the reference details at left...
3.	Amenorrhea 08/01/1985 - "A high incidence of amenorrhea (89%) due to ovarian function suppression was observed for the group receiving CMFp alone. " 11/01/1980 - "Amenorrhea developed within 10 months of starting therapy in 13 of 15 patients given CMF, 8 of 10 receiving CMFP, and all of 13 CMFPT-treated patients. " 11/01/1980 - "CMFP-induced amenorrhea was associated with similar changes in the plasma estrogens and gonadotropins, but patients receiving this combination showed significantly greater reductions in plasma androstenedione and also decreased levels of plasma dehydroepiandrosterone sulfate. " Order ALL the reference details at left...
4.	Breast Neoplasms (Breast Cancer) 10/01/1992 - "CMFP/AV is a well-tolerated, effective regimen in advanced breast cancer but does not appear to be superior to CMFP alone." 05/15/1989 - "Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer." 03/01/1986 - "Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors." 07/01/1985 - "Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors." 04/01/1984 - "High-dose versus low-dose CMFP regimen in advanced breast cancer." Order ALL the reference details at left...
5.	Vomiting 05/15/1989 - "It is concluded that despite a higher response rate on CMFP and some differences in toxicities including a higher reported incidence of emesis on CFP, there was no substantial difference in efficacy or tolerability between the two regimens." 05/15/1989 - "Emesis was more frequent on CFP (49%) than on CMFP (26%) but was severe in only 7% and 5%, respectively. " 10/01/1982 - "There was also more emesis with CMF than with CMFP (P = 0.006). " 07/01/1985 - "There was significantly more nausea and vomiting after CAF treatment, and CMFP treatment was associated with significantly more edema, Cushingoid features, fever, and eye symptoms." 10/01/1982 - "AV was associated with fewer infections than CMFP (P = 0.02), less diarrhea than CMFP (P = 0.04), more emesis than CMF (P = 0.02), and more neurologic toxicity than either CMF or CMFP (P less than 0.0001). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	Dehydroepiandrosterone Sulfate
3.	Gonadotropins
4.	Androstenedione (4 Androstene 3,17 dione)
5.	Methotrexate (Mexate)
6.	Fluorouracil (Carac)
7.	Cyclophosphamide (Cytoxan)
8.	Prednisone (Sone)
9.	Tamoxifen
10.	Vincristine (Oncovin)

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)
2.	Drug Therapy (Chemotherapy)
3.	Simple Mastectomy
4.	Mastectomy (Mammectomy)
5.	Combination Drug Therapy (Combination Chemotherapy)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>